Navigation Links
CuraGen Advances CR011-vcMMAE into Phase II
Date:4/9/2008

- Clinical trial expanded to further evaluate activity of CR011-vcMMAE for

advanced melanoma - - Preliminary Phase I/II results to be presented in June at 2008 ASCO

Annual Meeting -

BRANFORD, Conn., April 9, 2008 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today that it has advanced CR011-vcMMAE, an antibody-drug conjugate (ADC), into Phase II for the treatment of patients with unresectable Stage III and Stage IV melanoma. CuraGen also announced today that updated data from the ongoing Phase I/II trial with CR011-vcMMAE will be presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30 - June 3, 2008 in Chicago, IL.

"We are pleased with the progress achieved in the CR011-vcMMAE clinical program," commented Dr. Ronit Simantov, Vice President of Medical Development and Chief Medical Officer. "Advancing this program into Phase II is an important development milestone as we look to establish the role of CR011-vcMMAE in the treatment of patients with advanced melanoma."

"Antibodies have made a significant impact in cancer treatment, and we believe that ADCs represent the next generation of antibody technologies. Over the last year, ADCs have demonstrated proof-of-concept activity against both solid tumors and hematologic malignancies," said Dr. Timothy M. Shannon, President and Chief Executive Officer of CuraGen. "We are encouraged by the activity observed to date with CR011-vcMMAE and are looking forward to reporting updated results at ASCO in June."

CR011-vcMMAE is an ADC comprised of a fully-human monoclonal antibody aga
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
2. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
3. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
4. CuraGen Announces Top-Line Phase II Results on Velafermin
5. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
6. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
7. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
8. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
9. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
10. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
11. Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)..., MIAMI, Nov. 9 ISTA P...nced additional results from the Company,s Bepreve...5% Phase 3 clinical studies. These results were p...ting of the American College of Allergy, Asthma &a...In a poster presentation titled, "Treatment of Ocu...
(Date:11/9/2009)..., SUNNYVALE, Calif., Nov. 9 /PRNewswire-FirstCal...harmaceutical company focused on developing and co...the treatment of immune mediated diseases and canc...sident, Preclinical Development will provide an ov... Merriman Curhan Ford,s 6th Annual Investor Summit...
(Date:11/9/2009)..., SOUTH SAN FRANCISCO, Calif., Nov. 9 /PRNewswir...ay announced that on November 5, 2009, it received...q") stating that the Nasdaq Hearing Panel has gran... NASDAQ Global Market subject to the condition tha...er 31, 2009, the proposed merger (the "Merger") co...
Breaking Medicine Technology:ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 2ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 3Pharmacyclics to Present at Merriman Curhan Ford's Investor Summit 2009 2Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing 2Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing 3David Yap receives Amethyst Award 51065 1LocumTenens com Expands Service Lines to Include Primary Care 51062 1LocumTenens com Expands Service Lines to Include Primary Care 51062 2LocumTenens com Expands Service Lines to Include Primary Care 51062 3Insite Security Partners With WorldClinic to Offer Global Medical Support to Clients 51057 1Insite Security Partners With WorldClinic to Offer Global Medical Support to Clients 51057 2Insite Security Partners With WorldClinic to Offer Global Medical Support to Clients 51057 3Insite Security Partners With WorldClinic to Offer Global Medical Support to Clients 51057 4
...3 Telik, Inc.,(Nasdaq: TELK ) announced it will ... of TELINTRA(R) (ezatiostat HCl) Tablets at the 49...ology. The presentation is,scheduled for Saturday,...,and B4 at the Georgia World Congress Center in At...608) is titled: "Phase 1 Dose Escalation Study of,...
...ance to Phase III Clinical Trial, PALO ALTO, Cali...d: AVGO), a late-stage biotechnology company that,...eurodegenerative,diseases, today announced positiv...AL-08, the Company,s second generation proprietary...ose of the trial was to determine which,of two com...
Other Medicine Technology:Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) 2Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) 3Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) 4
(Date:11/9/2009)... The American Academy of...an 75,000 clinically practicing physician assistan... the U.S. House of Representatives for passing Sat...Affordable Health Care for America Act. ,, "We ...l ultimately lower the cost of health care and gre...
(Date:11/9/2009)...use funds to move lab findings into human therapy ...n from nerve damage ,, ANN ARBOR, Mich., Nov. ...niversity of Michigan Department of Neurology have...therapy for neuropathic pain, a difficult-to-treat...se of damage to nerve without obvious tissue injur...
(Date:11/9/2009)...ble in French . , , Montreal, November 9, 20...emale. In human bodies trillions of cells are coup... are composed. Yet these don,t come in twos, they...cause these complex cell networks are the backbone...ed for ways to splice cell clusters down to their ...
(Date:11/9/2009)...9, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the ...announced the availability of INTUNIV (guanfacine)... United States for the treatment of Attention-Defi...adolescents ages 6 to 17. INTUNIV, a once-daily f...nscheduled alpha-2A receptor agonist approved for ...
(Date:11/9/2009)...eople around the world suffer from cataracts. Thom...d his coauthors discuss cataract surgery with the ...issue of Deutsches rzteblatt International ( Dts...lindness is usually due to opacification of the le...perations are performed each year. Cataracts can b...
Breaking Medicine News(10 mins):Health News:American Academy of Physician Assistants Applauds U.S. House of Representatives for Passing Health Care Reform Bill 2Health News:U-M Researchers Receive $1.8 Million Grant to Develop New Therapy for Neuropathic Pain 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 3Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 4
...arry Minnix, President & CEO, American Association...ation of the Medicare Therapy,Caps Exceptions Proc...,from Larry Minnix, President & CEO, American Asso...in having their physical and,occupational therapy ...
... The American Medical,Association (AMA) Foundation...ysician association, recently named several new bo...ers:, -- Jean Howard, Traverse City, MI, Preside...aynard, M.D., Evansville, IN, Secretary, New Mem...
...l sunscreen available at retailers nationwide and ... , ORLANDO, Fla., July 2 Caribbean Solutions,( h...een, Caribbean Sol,SolGuard SPF 25 and Kids Kare 2...ttp://www.newscom.com/cgi-bin/prnh/20080702/LAW520...
... only to childbirth as most common reason for hosp..., July 2 (HealthDay News) -- In 2006, more than 1....opulation of Dallas -- were hospitalized for pneum...mission to hospital, and treating these lung infec...
...Technologies from Los Alamos National Laboratory ... Airplanes, Cars Go On a Nanotechnology ...fics (Pink Sheets: MHTX) announced today that it h...enator,Jeff Bingaman said, "I believe the merger o...
...(July 2, 2008) - Measuring calcium deposits in the...isk in American adults, even when they are elderly...ssue of Journal of the American College of Cardio...l Center (LA BioMed), said previous studies had fo...
Other Medicine News:Health News:AAHSA Statement: Therapy Caps Ration Care 2Health News:Caribbean Sol Biodegradable Sunscreen Gets Strong Safety Rating From Environmental Working Group 2Health News:Manhattan Scientifics Acquires Metallicum, Inc. 2Health News:Manhattan Scientifics Acquires Metallicum, Inc. 3Health News:Manhattan Scientifics Acquires Metallicum, Inc. 4Health News:New study finds coronary arterial calcium scans help detect overall death risk in the elderly 2
Steroid 21-Hydroxylase (21-OH) Autoantibody RIA
...ELISA test kit is intended for the quantitative de...This exceptionally sensitive ELISA procedure offer...y), providing for accurate establishment of post-a...ventional methods. Furthermore, with the ability t...
...r use with 4, 8, or 12 channel pipettors. Angled s...rly all of the solution. Corners have pouring lips...rgin polystyrene containing no regrinds. Sterile 5...y irradiation. Dimensions: 78 mm W x 152 mm L x 35...
Sterile Individually Packed 100 mL Solution Basins
Medicine Products: